Phillip A Thompson (Philip Thompson, Philip A Thompson)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 44

Top Topics

Tyrosine Kinase

Chronic Lymphocytic Leukemia

Top Venues

Blood cancer journal

This page only lists publications with an associated author ORCID identifier.

Publications

Constantine S Tam, Phillip A Thompson
BTK inhibitors in CLL: second-generation drugs and beyond. Blood advances 8 (9) (2024)
Thomas E Lew, Rory Bennett, Victor S Lin, Ashley Whitechurch, Sasanka Mithila Handunnetti, Paula Marlton, Yandong Shen, Stephen P Mulligan, Joshua Casan, Piers Blombery, Constantine S Tam, Andrew W Roberts, John Francis Seymour, Phillip A Thompson, Mary A Anderson
Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon. Blood advances 8 (6) (2024)
Phillip A Thompson
Ending endless follow-up for low-risk CLL? Blood advances 8 (16) (2024)
Sasanka Mithila Handunnetti, Mary Ann Anderson, Kate I Burbury, Phillip A Thompson, Glenda Burke, Mathias Bressel, Juliana L Di Iulio, Rodney John Hicks, David A Westerman, Stephen Lade, Christiane Pott, Rishu Agarwal, Rachel M Koldej, David Ritchie, Martin Dreyling, Mark A Dawson, Sarah-Jane Dawson, John Francis Seymour, Andrew W Roberts, Constantine S Tam
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions. Blood (2024)
Paul Joseph Hampel, Mahesh Swaminathan, Kerry A Rogers, Erin M Parry, Jan A Burger, Matthew S Davids, Wei Ding, Alessandra Ferrajoli, Jonathan Mitry Hyak, Nitin Jain, Saad S Kenderian, Yucai Wang, William G Wierda, Jennifer A Woyach, Sameer A Parikh, Phillip A Thompson
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. Blood advances 8 (10) (2024)
Paul Joseph Hampel, Mahesh Swaminathan, Kerry A Rogers, Erin M Parry, Jan A Burger, Matthew S Davids, Wei Ding, Alessandra Ferrajoli, Jonathan Mitry Hyak, Nitin Jain, Saad S Kenderian, Yucai Wang, William G Wierda, Jennifer A Woyach, Sameer A Parikh, Phillip A Thompson
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. Blood advances 8 (10) (2024)
Constantine S Tam, Phillip A Thompson
BTK Inhibitors in CLL : Second Generation Drugs and Beyond. Blood advances (2024)
Paul Joseph Hampel, Mahesh Swaminathan, Kerry A Rogers, Erin M Parry, Jan A Burger, Matthew S Davids, Wei Ding, Alessandra Ferrajoli, Jonathan Mitry Hyak, Nitin Jain, Saad S Kenderian, Yucai Wang, William G Wierda, Jennifer A Woyach, Sameer A Parikh, Phillip A Thompson
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. Blood advances (2024)
Constantine S Tam, Phillip A Thompson
BTK inhibitors in CLL: second-generation drugs and beyond. Blood advances 8 (9) (2024)
Sasanka Mithila Handunnetti, Mary Ann Anderson, Kate I Burbury, Phillip A Thompson, Glenda Burke, Mathias Bressel, Juliana Di Iulio, Rodney John Hicks, David Westerman, Stephen Lade, Christiane Pott, Rishu Agarwal, Rachel M Koldej, David S Ritchie, Martin Dreyling, Mark A Dawson, Sarah-Jane Dawson, John Francis Seymour, Andrew W Roberts, Constantine S Tam
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions. Blood 144 (8) (2024)
Constantine S Tam, Phillip A Thompson
BTK inhibitors in CLL: second-generation drugs and beyond. Blood advances 8 (9) (2024)
Phillip A Thompson
Ending endless follow-up for low-risk CLL? Blood advances 8 (16) (2024)
Constantine S Tam, Phillip A Thompson
BTK inhibitors in CLL: second-generation drugs and beyond. Blood advances 8 (9) (2024)
Paul Joseph Hampel, Mahesh Swaminathan, Kerry A Rogers, Erin M Parry, Jan A Burger, Matthew S Davids, Wei Ding, Alessandra Ferrajoli, Jonathan Mitry Hyak, Nitin Jain, Saad S Kenderian, Yucai Wang, William G Wierda, Jennifer A Woyach, Sameer A Parikh, Phillip A Thompson
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. Blood advances 8 (10) (2024)
Thomas E Lew, Rory Bennett, Victor S Lin, Ashley Whitechurch, Sasanka Mithila Handunnetti, Paula Marlton, Yandong Shen, Stephen P Mulligan, Joshua Casan, Piers Blombery, Constantine S Tam, Andrew W Roberts, John Francis Seymour, Phillip A Thompson, Mary A Anderson
Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon. Blood advances 8 (6) (2024)
Paul Joseph Hampel, Mahesh Swaminathan, Kerry A Rogers, Erin M Parry, Jan A Burger, Matthew S Davids, Wei Ding, Alessandra Ferrajoli, Jonathan Mitry Hyak, Nitin Jain, Saad S Kenderian, Yucai Wang, William G Wierda, Jennifer A Woyach, Sameer A Parikh, Phillip A Thompson
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. Blood advances 8 (10) (2024)
Thomas E Lew, Rory Bennett, Victor S Lin, Ashley Whitechurch, Sasanka Mithila Handunnetti, Paula Marlton, Yandong Shen, Stephen P Mulligan, Joshua Misha Lewis Casan, Piers Blombery, Constantine S Tam, Andrew W Roberts, John Francis Seymour, Phillip A Thompson, Mary Ann Anderson
Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon. Blood advances (2024)
Paul Joseph Hampel, Mahesh Swaminathan, Kerry A Rogers, Erin M Parry, Jan A Burger, Matthew S Davids, Wei Ding, Alessandra Ferrajoli, Jonathan Mitry Hyak, Nitin Jain, Saad S Kenderian, Yucai Wang, William G Wierda, Jennifer A Woyach, Sameer A Parikh, Phillip A Thompson
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. Blood advances 8 (10) (2024)
Kelly Sharon Chien, Christine B Peterson, Elliana Young, Dai Chihara, Elizabet E Manasanch, Jeremy Ramdial, Phillip A Thompson
Outcomes of Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies. Blood advances (2023)
Alexandre Bazinet, Tapan M Kadia, Nicholas James Short, Gautam Borthakur, Sa A Wang, Wei Wang, Sanam Loghavi, Jeffrey L Jorgensen, Keyur Pravinchandra Patel, Courtney D D DiNardo, Naval G Daver, Yesid Alvarado, Fadi G Haddad, Sherry R Pierce, Graciela Nogueras Gonzalez, Abhishek Maiti, Koiji Sasaki, Musa Ylimaz, Phillip A Thompson, William G Wierda, Guillermo Garcia-Manero, Michael Andreeff, Elias J Jabbour, Marina Y Konopleva, Xuelin Huang, Hagop M Kantarjian, Farhad Ravandi
Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity. Blood advances (2023)
Kelly Sharon Chien, Christine B Peterson, Elliana Young, Dai Chihara, Elizabet E Manasanch, Jeremy Ramdial, Phillip A Thompson
Outcomes of Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies. Blood advances (2023)
Phillip A Thompson, Michael J Keating, Alessandra Ferrajoli, Nitin Jain, Christine B Peterson, Naveen Garg, Sa A Wang, Jeffrey L Jorgensen, Tapan Mahendra Kadia, Prithviraj Bose, Naveen Pemmaraju, Nicholas James Short, William G Wierda
Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD. Leukemia (2023)
Phillip A Thompson, Alexandre Bazinet, William G Wierda, Constantine S Tam, Susan M O'Brien, Satabdi Saha, Christine B Peterson, William Plunkett, Michael J Keating
Sustained remissions in CLL after frontline FCR treatment with very long-term follow-up. Blood (2023)
Phillip A Thompson, Constantine Tam
Pirtobrutinib: A New Hope for patients with BTK-inhibitor refractory lymphoproliferative disorders. Blood (2023)
Chaitra S Ujjani, Ted A Gooley, Stephen E Spurgeon, Deborah M Stephens, Catherine E Lai, Catherine M Broome, Susan M O'Brien, Haiying Zhu, Kerry J Laing, Allison M Winter, Georgios Pongas, Alexander L Greninger, David M Koelle, Tanya Siddiqi, Matthew S Davids, Kerry A Rogers, Alexey V Danilov, Amy L Sperling, Brian Tu, Tyler Sorensen, Kelsey M Launchbury, Carlissa J Burrow, Genesis Quezada, Joshua A Hill, Mazyar Shadman, Phillip A Thompson
Diminished Humoral and Cellular Responses to SARS-CoV-2 Vaccines in Patients with Chronic Lymphocytic Leukemia. Blood advances (2022)
Farhad Ravandi, Robert J Kreitman, Enrico Tiacci, Leslie Andritsos, Versha Banerji, Jacqueline C Barrientos, Seema A Bhat, James S Blachly, Alessandro Broccoli, Timothy Call, Dai Chihara, Claire Dearden, Judit Demeter, Sascha Dietrich, Monica Else, Narendranath Epperla, Brunangelo Falini, Francesco Forconi, Douglas E Gladstone, Alessandro Gozzetti, Sunil Iyengar, James B Johnston, Jeffrey L Jorgensen, Gunnar Juliusson, Francesco Lauria, Gerard Lozanski, Sameer A Parikh, Jae H Park, Aaron Polliack, Graeme Quest, Tadeusz Robak, Kerry A Rogers, Alan Saven, John Francis Seymour, Tamar Tadmor, Martin S Tallman, Constantine S Tam, Phillip A Thompson, Xavier Troussard, Clive S Zent, Thorsten Zenz, Pier Luigi Luigi Zinzani, Bernhard J Woermann, Kanti R Rai, Michael Grever
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood cancer journal 12 (12) (2022)
Chaitra S Ujjani, Ted A Gooley, Stephen E Spurgeon, Deborah M Stephens, Catherine E Lai, Catherine M Broome, Susan M O'Brien, Haiying Zhu, Kerry J Laing, Allison M Winter, Georgios Pongas, Alexander L Greninger, David M Koelle, Tanya Siddiqi, Matthew S Davids, Kerry A Rogers, Alexey V Danilov, Amy L Sperling, Brian Tu, Tyler Sorensen, Kelsey M Launchbury, Carlissa J Burrow, Genesis Quezada, Joshua A Hill, Mazyar Shadman, Phillip A Thompson
Diminished Humoral and Cellular Responses to SARS-CoV-2 Vaccines in Patients with Chronic Lymphocytic Leukemia. Blood advances (2022)
Uri Rozovski, Ivo Veletic, David M Harris, Ping Li, Zhiming Liu, Preetesh Jain, Taghi Manshouri, Alessandra Ferrajoli, Jan A Burger, Prithviraj Bose, Phillip A Thompson, Nitin Jain, William G Wierda, Srdan Verstovsek, Michael J Keating, Zeev E Estrov
STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. Journal of immunology (Baltimore, Md. : 1950) 208 (12) (2022)
Nitin Jain, Jayastu Senapati, Beenu Thakral, Alessandra Ferrajoli, Phillip A Thompson, Jan A Burger, Sreyashi Basu, Tapan M Kadia, Naval G Daver, Gautam Borthakur, Marina Konopleva, Naveen Pemmaraju, Erin M Parry, Catherine J Wu, Joseph D Khoury, Carlos E Bueso-Ramos, Naveen Garg, Xuemei Wang, Wanda Lopez, Ana Ayala, Susan M O'Brien, Hagop M Kantarjian, Michael J Keating, James P Allison, Padmanee Sharma, William G Wierda
A Phase 2 Study of Nivolumab Combined with Ibrutinib in Patients with Diffuse Large B-cell Richter Transformation of CLL. Blood advances (2022)
Farhad Ravandi, Robert J Kreitman, Enrico Tiacci, Leslie Andritsos, Versha Banerji, Jacqueline C Barrientos, Seema A Bhat, James S Blachly, Alessandro Broccoli, Timothy Call, Dai Chihara, Claire Dearden, Judit Demeter, Sascha Dietrich, Monica Else, Narendranath Epperla, Brunangelo Falini, Francesco Forconi, Douglas E Gladstone, Alessandro Gozzetti, Sunil Iyengar, James B Johnston, Jeffrey L Jorgensen, Gunnar Juliusson, Francesco Lauria, Gerard Lozanski, Sameer A Parikh, Jae H Park, Aaron Polliack, Graeme Quest, Tadeusz Robak, Kerry A Rogers, Alan Saven, John Francis Seymour, Tamar Tadmor, Martin S Tallman, Constantine S Tam, Phillip A Thompson, Xavier Troussard, Clive S Zent, Thorsten Zenz, Pier Luigi Luigi Zinzani, Bernhard J Woermann, Kanti R Rai, Michael Grever
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood cancer journal 12 (12) (2022)
Farhad Ravandi, Robert J Kreitman, Enrico Tiacci, Leslie Andritsos, Versha Banerji, Jacqueline C Barrientos, Seema A Bhat, James S Blachly, Alessandro Broccoli, Timothy Call, Dai Chihara, Claire Dearden, Judit Demeter, Sascha Dietrich, Monica Else, Narendranath Epperla, Brunangelo Falini, Francesco Forconi, Douglas E Gladstone, Alessandro Gozzetti, Sunil Iyengar, James B Johnston, Jeffrey L Jorgensen, Gunnar Juliusson, Francesco Lauria, Gerard Lozanski, Sameer A Parikh, Jae H Park, Aaron Polliack, Graeme Quest, Tadeusz Robak, Kerry A Rogers, Alan Saven, John Francis Seymour, Tamar Tadmor, Martin S Tallman, Constantine S Tam, Phillip A Thompson, Xavier Troussard, Clive S Zent, Thorsten Zenz, Pier Luigi Luigi Zinzani, Bernhard J Woermann, Kanti R Rai, Michael Grever
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood cancer journal 12 (12) (2022)
Farhad Ravandi, Robert J Kreitman, Enrico Tiacci, Leslie Andritsos, Versha Banerji, Jacqueline C Barrientos, Seema A Bhat, James S Blachly, Alessandro Broccoli, Timothy Call, Dai Chihara, Claire Dearden, Judit Demeter, Sascha Dietrich, Monica Else, Narendranath Epperla, Brunangelo Falini, Francesco Forconi, Douglas E Gladstone, Alessandro Gozzetti, Sunil Iyengar, James B Johnston, Jeffrey L Jorgensen, Gunnar Juliusson, Francesco Lauria, Gerard Lozanski, Sameer A Parikh, Jae H Park, Aaron Polliack, Graeme Quest, Tadeusz Robak, Kerry A Rogers, Alan Saven, John Francis Seymour, Tamar Tadmor, Martin S Tallman, Constantine S Tam, Phillip A Thompson, Xavier Troussard, Clive S Zent, Thorsten Zenz, Pier Luigi Luigi Zinzani, Bernhard J Woermann, Kanti R Rai, Michael Grever
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood cancer journal 12 (12) (2022)
Phillip A Thompson, Xianli Jiang, Pinaki Banerjee, Rafet Basar, Naveen Garg, Ken Chen, Mecit Kaplan, Vandana Nandivada, Ana Karen Nunez Cortes, Alessandra Ferrajoli, Michael J Keating, Christine B Peterson, Michael Andreeff, Katayoun Rezvani, William G Wierda
A phase two study of high dose blinatumomab in Richter's syndrome. Leukemia 36 (9) (2022)
Ti'ara L Griffen, Fieke W Hoff, Yihua Qiu, James W Lillard, Alessandra Ferrajoli, Phillip A Thompson, Endurance Toro, Kevin Ruiz, Jan A Burger, William G Wierda, Steven Mitchell Kornblau
Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets. Blood cancer journal 12 (3) (2022)
Farhad Ravandi, Robert J Kreitman, Enrico Tiacci, Leslie Andritsos, Versha Banerji, Jacqueline C Barrientos, Seema A Bhat, James S Blachly, Alessandro Broccoli, Timothy Call, Dai Chihara, Claire Dearden, Judit Demeter, Sascha Dietrich, Monica Else, Narendranath Epperla, Brunangelo Falini, Francesco Forconi, Douglas E Gladstone, Alessandro Gozzetti, Sunil Iyengar, James B Johnston, Jeffrey L Jorgensen, Gunnar Juliusson, Francesco Lauria, Gerard Lozanski, Sameer A Parikh, Jae H Park, Aaron Polliack, Graeme Quest, Tadeusz Robak, Kerry A Rogers, Alan Saven, John Francis Seymour, Tamar Tadmor, Martin S Tallman, Constantine S Tam, Phillip A Thompson, Xavier Troussard, Clive S Zent, Thorsten Zenz, Pier Luigi Luigi Zinzani, Bernhard J Woermann, Kanti R Rai, Michael Grever
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood cancer journal 12 (12) (2022)
Chaitra S Ujjani, Ted A Gooley, Stephen E Spurgeon, Deborah M Stephens, Catherine E Lai, Catherine M Broome, Susan M O'Brien, Haiying Zhu, Kerry J Laing, Allison M Winter, Georgios Pongas, Alexander L Greninger, David M Koelle, Tanya Siddiqi, Matthew S Davids, Kerry A Rogers, Alexey V Danilov, Amy L Sperling, Brian Tu, Tyler Sorensen, Kelsey M Launchbury, Carlissa J Burrow, Genesis Quezada, Joshua A Hill, Mazyar Shadman, Phillip A Thompson
Diminished Humoral and Cellular Responses to SARS-CoV-2 Vaccines in Patients with Chronic Lymphocytic Leukemia. Blood advances (2022)
Francesco Paolo Tambaro, Harjeet Singh, Emily Jones, Michael Rytting, Kris Michael Mahadeo, Phillip A Thompson, Naval Daver, Courtney D D DiNardo, Tapan Mahendra Kadia, Guillermo Garcia Manero, Tim Chan, Rutul R Shah, William G Wierda
Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia 35 (11) (2021)
Abhishek Maiti, Courtney D D DiNardo, Naval G Daver, Caitlin R Rausch, Farhad Ravandi, Tapan Mahendra Kadia, Naveen Pemmaraju, Gautam Borthakur, Prithviraj Bose, Ghayas C Issa, Nicholas James Short, Musa Yilmaz, Guillermo Montalban-Bravo, Alessandra Ferrajoli, Elias J Jabbour, Nitin Jain, Maro Ohanian, Koichi Takahashi, Phillip A Thompson, Sanam Loghavi, Kathryn S Montalbano, Sherry Pierce, William G Wierda, Hagop M Kantarjian, Marina Y Konopleva
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood cancer journal 11 (2) (2021)
Nitin Jain, Phillip A Thompson, Jan A Burger, Alessandra Ferrajoli, Koichi Takahashi, Zeev E Estrov, Gautam Borthakur, Prithviraj Bose, Tapan Mahendra Kadia, Naveen Pemmaraju, Koiji Sasaki, Marina Y Konopleva, Elias J Jabbour, Naveen Garg, Xuemei Wang, Rashmi Kanagal-Shamana, Keyur Pravinchandra Patel, Wei Wang, Jeffrey Jorgensen, Sa Wang, Wanda Lopez, Ana Ayala, William Plunkett, Varsha Gandhi, Hagop M Kantarjian, Susan O'Brien, Michael Keating, William G Wierda
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia 35 (12) (2021)
Rong Chen, Jennifer Tsai, Phillip A Thompson, Yuling Chen, Ping Xiong, Chaomei Liu, Francis Burrows, Mariela Sivina, Jan A Burger, Michael J Keating, William G Wierda, William Plunkett
The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action. Blood cancer journal 11 (3) (2021)
Uri Rozovski, David M Harris, Ping Li, Zhiming Liu, Preetesh Jain, Alessandra Ferrajoli, Jan A Burger, Prithviraj Bose, Phillip A Thompson, Nitin Jain, William G Wierda, Orit Uziel, Michael J Keating, Zeev E Estrov
STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage. Journal of immunology (Baltimore, Md. : 1950) 203 (11) (2019)
Ekaterina Kim, Elisa Ten Hacken, Mariela Sivina, Astrid Clarke, Phillip A Thompson, Nitin Jain, Alessandra Ferrajoli, Zeev Estrov, Michael J Keating, William G Wierda, Kapil N Bhalla, Jan A Burger
The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia 34 (6) (2019)
Paolo Strati, Alessandra Ferrajoli, William G Wierda, Nitin Jain, Phillip A Thompson, Susan M O'Brien, Katy Rezvani, Hagop M Kantarjian, Jan A Burger, Christina O Hinojosa, Michael J Keating, Zeev Estrov
Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. Leukemia 32 (10) (2018)
Phillip A Thompson, Christine B Peterson, Paolo Strati, Jeff Jorgensen, Michael J Keating, Susan M O'Brien, Alessandra Ferrajoli, Jan A Burger, Zeev Estrov, Nitin Jain, Tapan Mahendra Kadia, Gautam Borthakur, Courtney D DiNardo, Naval Daver, Elias Jabbour, William G Wierda
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia 32 (11) (2018)